4.2 Article

Therapeutic implications of accurate classification of pituitary adenomas

期刊

SEMINARS IN DIAGNOSTIC PATHOLOGY
卷 30, 期 3, 页码 158-164

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semdp.2013.06.002

关键词

Pituitary adenoma; Classification; Pegvisomant; Temozolomide; Dopamine agonists; Somatostatin

向作者/读者索取更多资源

Recent data suggest that 1 of 5 individuals in the general population is affected with a pituitary adenoma. Many of these neoplasms are clinically non-functioning adenomas that may be small and clinically undetected or may present as mass lesions; others are hormonally active and cause significant morbidity due to the metabolic effects of hormone excess (e.g., acromegaly and cushing's disease). In either case, they can grow and invade adjacent anatomic structures. Tumors with similar clinical features are morphologically heterogenous and detailed comprehensive classification of pituitary adenomas is important to predict specific clinical behaviors and genetic changes that serve as targets for therapy. We provide a practical approach to clinical diagnosis and highlight the pitfalls in the classification of these common neoplasms. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据